Brooks Automation market cap is $7.4 b, and annual revenue was $780.85 m in FY 2019

Brooks Automation Gross profit (Q2, 2021)127.3 M

Brooks Automation Gross profit margin (Q2, 2021), %44.4%

Brooks Automation Net income (Q2, 2021)23.7 M

Brooks Automation EBIT (Q2, 2021)30.5 M

Brooks Automation Cash, 31-Mar-2021320.1 M

Brooks Automation EV7.1 B

Brooks Automation revenue was $780.85 m in FY, 2019 which is a 23.6% year over year increase from the previous period.

Brooks Automation revenue breakdown by business segment: 42.8% from Brooks Life Science Systems and 57.2% from Brooks Semiconductor Solutions Group

Brooks Automation revenue breakdown by geographic segment: 41.9% from North America , 6.2% from United Kingdom, 40.0% from Asia / Pacific / Other and 11.9% from Rest of Europe

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 692.9m | 631.6m | 780.8m |

| 24% | (9%) | 24% |

## Cost of goods sold | 425.5m | 385.5m | 464.6m |

## Gross profit | 267.4m | 246.1m | 316.3m |

| 39% | 39% | 41% |

## R&D expense | 47.0m | 46.9m | 56.4m |

## General and administrative expense | 153.1m | 167.0m | 212.0m |

## Operating expense total | 203.3m | 214.7m | 270.2m |

## EBIT | 64.1m | 31.4m | 46.0m |

| 9% | 5% | 6% |

## Interest expense | 408.0k | 9.5m | 22.3m |

## Interest income | 464.0k | 1.9m | 1.4m |

## Pre tax profit | 65.4m | 20.5m | 9.4m |

## Income tax expense | 12.1m | (47.3m) | (111.0k) |

## Net Income | 62.6m | 116.5m | 437.4m |

## EPS | 0.9 | 1.6 | 6.0 |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 101.6m | 197.7m | 301.6m |

## Accounts Receivable | 120.8m | 125.2m | 165.6m |

## Inventories | 106.4m | 97.0m | 99.4m |

## Current Assets | 352.0m | 564.1m | 647.1m |

## PP&E | 58.5m | 60.0m | 100.7m |

## Goodwill | 233.6m | 255.9m | 488.6m |

## Total Assets | 766.6m | 1.1b | 1.5b |

## Accounts Payable | 49.1m | 55.9m | 58.9m |

## Short-term debt | 2.0m | 829.0k | |

## Current Liabilities | 146.8m | 164.6m | 272.3m |

## Long-term debt | 194.1m | 50.3m | |

## Total Debt | 196.1m | 51.1m | |

## Total Liabilities | 159.0m | 377.4m | 377.0m |

## Common Stock | 833.0k | 841.0k | 857.0k |

## Additional Paid-in Capital | 1.9b | 1.9b | 1.9b |

## Retained Earnings | (1.1b) | (994.1m) | (586.4m) |

## Total Equity | 607.6m | 717.8m | 1.1b |

## Debt to Equity Ratio | 0.3 x | 0 x | |

## Debt to Assets Ratio | 0.2 x | 0 x | |

## Financial Leverage | 1.3 x | 1.5 x | 1.3 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | 62.6m | 116.5m | 437.4m |

## Depreciation and Amortization | 28.1m | 37.4m | 54.5m |

## Accounts Receivable | 11.2m | (28.5m) | (11.4m) |

## Inventories | 12.8m | (24.4m) | (2.9m) |

## Accounts Payable | 7.8m | 5.5m | 4.7m |

## Cash From Operating Activities | 96.2m | 74.0m | 90.9m |

## Purchases of PP&E | (12.7m) | (12.8m) | (23.9m) |

## Cash From Investing Activities | (54.2m) | (148.5m) | 211.3m |

## Long-term Borrowings | (1.5m) | (1.2m) | |

## Dividends Paid | (27.9m) | (28.3m) | (28.9m) |

## Cash From Financing Activities | (25.9m) | 170.3m | (191.2m) |

## Net Change in Cash | 16.5m | 96.1m | 107.5m |

## Interest Paid | 200.0k | 6.5m | 20.8m |

## Income Taxes Paid | 8.1m | 21.1m | 17.0m |

USD | Q1, 2017 |
---|---|

## Financial Leverage | 1.3 x |

FY, 2017 | FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | FY, 2019 | Q1, 2020 | |
---|---|---|---|---|---|---|---|

## Remaining Performance Obligations | $36.36 m | $30.36 m | $30.76 m | $28.42 m | $35.41 m | ||

## Twelve-Month Remaining Performance Obligations | $11.11 m | $16.12 m | $21.59 m | $22.46 m | $25.01 m | ||

## Backlog (Brooks Semiconductor Solutions Group) | $115 m | $124 m | $127 m | ||||

## Backlog (Brooks Life Science Systems) | $250 m | $273 m | $303 m | ||||

## Enterprise Customers (Brooks Life Science Systems) | 800 | 1.2 k | 1.5 k | ||||

## Enterprise Customers (GENEWIZ) | 4 k | 4 k | |||||

## Patents (US) | 420 | 365 | 385 | ||||

## Patents Pending (US) | 115 | 90 | 95 |